Axsome Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Axsome Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-275.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Healthcare companies in United States.
Cash Locked Ratio
$29For every $100 of sales, $29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $7 tied up three years earlier.
More money tied up than 63% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$1Sales grew 1,176% in 3 years; of every extra $100 of sales, $1 became extra profit.
Lower than 67% of Healthcare companies in United States.
Asset Productivity Ratio
+1176% / +108%In 3 years sales changed by +1176% while total assets changed by +108%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-1.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Lower than 65% of Healthcare companies in United States.
Tangible Assets Ratio
92%Of every $100 the company owns, $92 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
40%Of every $100 of net worth, $40 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 58% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Axsome Therapeutics, Inc. made a loss over the last year. Axsome Therapeutics, Inc. owes $0.89 for every $1 it owns. Axsome Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAxsome Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
98.14The share price is 98.14 times Axsome Therapeutics, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$8.2 BThe total market value of all of Axsome Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$83 MWhat Axsome Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.59Net worth divided by the number of shares. The share price of $156.07 is 98.1 times this, which is the P/B above.
Return on equity (ROE)
-245.1%Axsome Therapeutics, Inc. lost 245.1% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
Owes vs Owns
0.89×Axsome Therapeutics, Inc. owes $0.89 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneAxsome Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+66%Revenue rose 66% in the year to Dec 2025, and grew 134% a year on average over 3 years.
Profit growth
LossAxsome Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-28.7%Axsome Therapeutics, Inc. lost $29 for every $100 of revenue.
Interest cover
Not coveredAxsome Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAxsome Therapeutics, Inc. held $105 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Axsome Therapeutics, Inc.: $8.2 B ÷ $83 M (30 Jun 2026) = 98.1.
What is Axsome Therapeutics, Inc.'s return on equity?
Axsome Therapeutics, Inc. lost 245.1% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
How much does Axsome Therapeutics, Inc. owe compared with what it owns?
Axsome Therapeutics, Inc. owes $0.89 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does Axsome Therapeutics, Inc. pay a dividend?
No. Axsome Therapeutics, Inc. does not currently pay a dividend.
Is Axsome Therapeutics, Inc.'s revenue growing?
Revenue rose 66% in the year to Dec 2025, and grew 134% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.